1. Home
  2. ELAB vs SLRX Comparison

ELAB vs SLRX Comparison

Compare ELAB & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELAB
  • SLRX
  • Stock Information
  • Founded
  • ELAB 2020
  • SLRX N/A
  • Country
  • ELAB United States
  • SLRX United States
  • Employees
  • ELAB N/A
  • SLRX N/A
  • Industry
  • ELAB
  • SLRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELAB
  • SLRX Health Care
  • Exchange
  • ELAB Nasdaq
  • SLRX Nasdaq
  • Market Cap
  • ELAB 3.2M
  • SLRX 2.9M
  • IPO Year
  • ELAB 2023
  • SLRX N/A
  • Fundamental
  • Price
  • ELAB $4.41
  • SLRX $4.65
  • Analyst Decision
  • ELAB
  • SLRX
  • Analyst Count
  • ELAB 0
  • SLRX 0
  • Target Price
  • ELAB N/A
  • SLRX N/A
  • AVG Volume (30 Days)
  • ELAB 2.3M
  • SLRX 124.5K
  • Earning Date
  • ELAB 08-13-2025
  • SLRX 08-12-2025
  • Dividend Yield
  • ELAB N/A
  • SLRX N/A
  • EPS Growth
  • ELAB N/A
  • SLRX N/A
  • EPS
  • ELAB N/A
  • SLRX N/A
  • Revenue
  • ELAB N/A
  • SLRX N/A
  • Revenue This Year
  • ELAB N/A
  • SLRX N/A
  • Revenue Next Year
  • ELAB N/A
  • SLRX N/A
  • P/E Ratio
  • ELAB N/A
  • SLRX N/A
  • Revenue Growth
  • ELAB N/A
  • SLRX N/A
  • 52 Week Low
  • ELAB $4.31
  • SLRX $4.61
  • 52 Week High
  • ELAB $1,842.11
  • SLRX $108.00
  • Technical
  • Relative Strength Index (RSI)
  • ELAB 30.58
  • SLRX 31.39
  • Support Level
  • ELAB $4.31
  • SLRX $4.61
  • Resistance Level
  • ELAB $5.42
  • SLRX $6.28
  • Average True Range (ATR)
  • ELAB 0.97
  • SLRX 0.54
  • MACD
  • ELAB -0.25
  • SLRX 0.05
  • Stochastic Oscillator
  • ELAB 1.16
  • SLRX 1.92

About ELAB Elevai Labs Inc.

PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.

About SLRX Salarius Pharmaceuticals Inc.

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Share on Social Networks: